Omeros' Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis

Author's Avatar
Nov 05, 2021

Omeros Corporation (Nasdaq: OMER) today announced that the first report describing the effects of lectin-pathway inhibition by narsoplimab on urinary complement levels in kidney disease was presented yesterday at the Annual Meeting of the American Society of Nephrology (ASN). The work, conducted by a consortium from Denmark and the United Kingdom and led by Peter Garred, MD, DMSc, Chair and Professor of Clinical Molecular Medicine at the University of Copenhagen, was detailed at the ASN Annual Meeting in a+poster entitled “Reduction of Urinary Levels of Lectin Pathway Complement Components in an IgA Vasculitis Patient after MASP-2 Inhibition with Narsoplimab”.